Improving outcomes in difficult bone cancers using multimodality therapy, including radiation: Physician and nursing perspectives

被引：15

作者：

Anderson P. ^{[1
]}

Salazar-Abshire M. ^{[1
]}

机构：

[1] Department of Pediatrics, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4009

来源：

Current Oncology Reports | 2006年 / 8卷 / 6期

关键词：

Osteosarcoma; Radiat Oncol Biol Phys; Samarium; Multimodality Therapy; Bone Cancer;

D O I：

10.1007/s11912-006-0069-6

中图分类号：

学科分类号：

摘要：

Principles of therapy are similar for Ewing's sarcoma and osteosarcoma. Chemotherapy or surgery alone cures few patients. Multimodality measures are needed for durable response. Quality of life and function are very important short- and long-term considerations. The spine, sacrum, pelvis, ankle, hand, mediastinum, pulmonary hilum, and chest wall are examples of bone cancer locations for which surgery is difficult. Patients with positive margins may need radiation and may experience systemic therapy delay, recurrence, loss of function, or any combination of these. When radiation is used as a means of local control, concomitant chemotherapy can increase its effectiveness. Options for difficult Ewing's sarcoma and osteosarcoma situations and multimodality solutions, including 1 mCi/kg of samarium and proton therapy, are discussed. Combination radiation and chemotherapy regimens are summarized, and organization of patients, caregivers, and medical teams for multimodality therapy is described, along with tools used in our institution that aid in this process. Copyright © 2006 by Current Science Inc.

引用

页码：415 / 422

页数：7

共 50 条

[11]

Folkman J., Angiogenesis, Annu Rev Med, 57, pp. 1-18, (2006)

[12]

Folkman J., Tumor angiogenesis, Adv Cancer Res, 43, pp. 175-203, (1985)

[13]

Bolontrade M.F., Zhou R.R., Kleinerman E.S., Vasculogenesis plays a role in the growth of Ewing's sarcoma in vivo, Clin Cancer Res, 8, pp. 3622-3627, (2002)

[14]

Ozaki T., Neumann T., Wai D., Et al., Chromosomal alterations in osteosarcoma cell lines revealed by comparative genomic hybridization and multicolor karyotyping, Cancer Genet Cytogenet, 140, pp. 145-152, (2003)

[15]

Akerman M., Dreinhofer K., Rydholm A., Et al., Cytogenetic studies on fine-needle aspiration samples from osteosarcoma and Ewing's sarcoma, Diagn Cytopathol, 15, pp. 17-22, (1996)

[16]

Sandberg A.A.L., Cytogenetics and molecular genetics of bone and soft-tissue tumors, Am J Med Genet, 115, pp. 189-193, (2002)

[17]

Burchill S.A., Ewing's sarcoma: Diagnostic, prognostic, and therapeutic implications of molecular abnormalities, J Clin Pathol, 56, pp. 96-102, (2003)

[18]

Riley R.D., Burchill S.A., Abrams K.R., Et al., A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family, Eur J Cancer, 39, pp. 19-30, (2003)

[19]

Kovar H., Ewing tumor biology: Perspectives for innovative treatment approaches, Adv Exp Med Biol, 532, pp. 27-37, (2003)

[20]

Zhou Z., Guan H., Duan X., Kleinerman E.S., Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma, Cancer, 104, pp. 1713-1720, (2005)

← 1 2 3 4 5 →